Stanford University has been awarded a grant from the U.S. National Institutes of Health (NIH) to begin a Phase 2 clinical trial of pulmonary arterial hypertension (PAH) treatment tiprelestat, the treatment’s developer announced. Tiakis Biotech said tiprelestat was found to be safe in earlier clinical trials involving more than 100 participants. The new trial, ATHENA, […] The post Stanford awarded NIH grant for PAH treatment clinical trial appeared first on Pulmonary Hypertension News.
